{"prompt": "['NCT03257267', 'Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'IND Number:', 'Regeneron Pharmaceuticals, Inc.', 'EudraCT number: 2017-000350-19', 'Clinical Study Protocol', 'AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF', \"REGN2810 VERSUS INVESTIGATOR'S CHOICE OF\", 'CHEMOTHERAPY IN RECURRENT OR METASTATIC CERVICAL', 'CARCINOMA', 'Compound:', 'REGN2810 (Cemiplimab)', 'Clinical Phase:', '3', 'Protocol Number:', 'R2810-ONC-1676/GOG-3016 (CVP1601) ENGOT-cx9', 'Protocol Version:', 'R2810-ONC-1676/GOG-3016 (CVP1601) ENGOT-cx9', 'Amendment 7', 'Amendment 7 Date of Issue', 'See appended electronic signature page', 'Amendment 6 Date of Issue', '26 May 2020', 'Amendment 5 Date of Issue', '08 Mar 2019', 'Amendment 4 Date of Issue', '16 Aug 2018', 'Amendment 3JP Date of Issue', '27 Apr 2018', 'Amendment 3 Date of Issue', '21 Mar 2018', 'Amendment 2 Date of Issue:', '03 Nov 2017', 'Amendment 1 Date of Issue:', '14 Jul 2017', 'Original Date of Issue:', '13 Apr 2017', 'Scientific/Medical Monitors:', 'Regeneron Pharmaceuticals, Inc.', '777 Old Saw Mill River Road', 'Tarrytown, NY 10591', 'Regeneron Pharmaceuticals, Inc.', 'Page 1 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Regeneron Pharmaceuticals, Inc.', 'Page 2 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'AMENDMENT HISTORY', 'Amendment 7', 'The Independent Data Monitoring Committee (IDMC) convened on 8 March 2021 to evaluate the', 'data from a planned formal interim analysis of overall survival (OS). The IDMC declared', \"superiority of OS in patients receiving cemiplimab as compared to investigator's choice (IC)\", 'chemotherapy. As a result of the assessment, protocol Amendment 7 is being implemented to', 'provide a mechanism for eligible patients randomized to chemotherapy to receive cemiplimab as', 'part of a cemiplimab Extension Phase.', 'Patients randomized to IC chemotherapy may screen to receive cemiplimab in the Extension Phase', 'up to and including 30 June 2021. Patients previously on IC chemotherapy may continue up to 96', 'weeks on cemiplimab as per the Schedule of Events for the cemiplimab Extension Phase (Table', '3).', 'All patients currently on cemiplimab may continue treatment up to 96 weeks. All patients', 'receiving cemiplimab will do so as per the Schedule of Events for the cemiplimab Extension Phase', '(Table 3).', 'Patients currently receiving IC chemotherapy (pemetrexed, gemcitabine, topotecan, irinotecan, or', 'vinorelbine) may continue to be treated as long as, in the opinion of the investigator, they are', 'continuing to derive benefit from the assigned treatment.', 'As of Amendment 7 retreatment is no longer an option. As of Amendment 7, follow-up visits', 'are no longer required.', 'Detailed changes are in the following table:', 'Description of Change', 'Brief Rationale', 'Section # and Name', 'Added a cemiplimab', 'This is due to the observed', 'Clinical Study Protocol Synopsis:', 'Extension Phase so that', 'superiority of OS in patients', 'Study Design', 'patients previously', 'receiving cemiplimab as', 'Section 5.1 Study Description and', 'randomized to the', 'compared to', 'Duration', 'IC chemotherapy arm can', 'IC chemotherapy at the', 'receive cemiplimab 350 mg', 'second interim analysis.', 'Section 5.1.2 End of Study', 'Q3W up to 96 weeks.', 'Cemiplimab continues to', 'Definition', 'Added language stating that', 'demonstrate a safety profile', 'Section 7.1.7 Note Regarding', 'consistent in class.', 'patients currently on', 'IDMC Interim Analysis 2 (new', 'cemiplimab will also transition', 'section)', 'to the cemiplimab Extension', 'Section 7.1.7.1 Cemiplimab', 'Phase with pared-down', 'Extension Phase of the Study (new', 'assessments up to 96 weeks', 'section)', '(inclusive of previous', 'cemiplimab therapy).', 'Table 3 Schedule of Events for', 'Cemiplimab Extension Phase (new', 'table)', 'Section 7.1.7.2 Footnotes for the', 'Schedule of Events Table 3 for the', 'Regeneron Pharmaceuticals, Inc.', 'Page 3 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}